Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.
about
Novel drugs that target the metabolic reprogramming in renal cell cancerTargeting amino acid metabolism in cancer growth and anti-tumor immune responsePathways and therapeutic targets in melanomaAmino acid deprivation using enzymes as a targeted therapy for cancer and viral infectionsSingle amino acid arginine deprivation triggers prosurvival autophagic response in ovarian carcinoma SKOV3Arginine depletion by arginine deiminase does not affect whole protein metabolism or muscle fractional protein synthesis rate in mice.Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.Investigational cancer drugs targeting cell metabolism in clinical development.Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors.Blocking autophagy enhanced cytotoxicity induced by recombinant human arginase in triple-negative breast cancer cells.Decreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine.Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.Evaluation of arginine deiminase treatment in melanoma xenografts using (18)F-FLT PET.Therapeutic interventions to disrupt the protein synthetic machinery in melanomaArginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction.Use of response surface method for maximizing the production of arginine deiminase by Pseudomonas putida.Oncogene-directed alterations in cancer cell metabolism.A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas.Systemic treatment of metastatic uveal melanoma: review of literature and future perspectivesReduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance.Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges.The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials.Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease.Drug-induced amino acid deprivation as strategy for cancer therapy.Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.Arginine deiminase: recent advances in discovery, crystal structure, and protein engineering for improved properties as an anti-tumor drug.Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions.Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer CellsArginine dependence of tumor cells: targeting a chink in cancer's armor.Purification, immobilization, and biochemical characterization of l-arginine deiminase from thermophilic Aspergillus fumigatus KJ434941: anticancer activity in vitro.Directed arginine deiminase evolution for efficient inhibition of arginine-auxotrophic melanomas.Arginine-Dual roles as an onconutrient and immunonutrient.Nanomedicines: a theranostic approach for hepatocellular carcinoma.Hydrophobic Mutagenesis and Semi-rational Engineering of Arginine Deiminase for Markedly Enhanced Stability and Catalytic Efficiency.Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1.A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.Oncogene-Driven Metabolic Alterations in Cancer.Global metabolomic profiling of uterine leiomyomas.Targeting Metabolism for Cancer Therapy.Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers.
P2860
Q26740187-9AFB93C5-2452-433D-BE0B-45A7DB267722Q26775425-FE48C8F4-0735-41EE-8026-49BFFD404C93Q26865736-E402944F-7202-4B1E-AEAC-D9A22B040F42Q30040775-D4123D25-8E23-4B85-883C-3BFAAB20B68EQ33759388-E9E38698-A56B-4F2D-8B47-2A492C5AE9ACQ35182189-984005A9-7B38-40F6-B6EE-2EE96C65033BQ35233239-099473C1-21EC-44B6-A7C7-DA12D18A068FQ35615701-08C5F2EC-0805-4127-9D94-CD2C9E713900Q35674875-B5FD9220-39ED-4656-AABF-493E8FF6F00AQ35679199-CB1FCC9D-51A8-404B-9E1A-6E7F7119EFD1Q35781589-9E4137F9-286C-4510-A6A6-3592B4054630Q35927116-8859E33E-8F1A-4604-9E50-B7CA24127241Q35957293-648E8AE8-6FDB-4F59-8267-B439B38DC46BQ36473355-1CF8711E-5B2D-41A1-95E6-050BD11CA719Q37339881-045667F5-70BC-4587-A0EF-959893658EB1Q37351509-227693E9-A733-4043-BE45-9D8D2805651FQ37395416-1280AFAD-6371-479A-BD8D-97EB01F9910FQ37465815-6CDA74DD-6F50-4A2E-A709-73C221EDAB9FQ37482566-716E0011-2DC6-420D-A179-05D707AD3D0EQ37688620-2312EA6E-4D3F-4EFD-82FF-52DFBF051760Q38181070-3E74CF6B-8649-4A31-95B9-8493BB30C888Q38223301-A1478772-B49A-4361-A837-E6C7DB67FD5CQ38441450-E7F9B819-1948-41EA-9FDE-7D419B53B3A8Q38657061-C300E0A8-B039-4614-AAA8-7487C9510FD2Q38733577-22A341CD-D9FF-41B4-998A-D49CC48BD3D3Q38777479-D39BC906-2AF2-41C1-A65E-2AF452780C7FQ38792334-9A3A8635-2E07-494B-9811-21012135B08CQ38814004-F344D905-AE59-4EB3-8221-77C4F6C96406Q38816145-A2CEA399-7FC9-4381-9F79-57D5E2491B3DQ38920582-6A1B975F-24CD-41F3-8052-8F1DCC9D9B8AQ38967935-238888E7-DF0A-407C-B0FB-93B2FD7977B1Q39012828-029BF38E-7A53-44FD-AD9E-FC8827C4340BQ40051560-5D6ECD7D-B69E-4566-AFBF-E0C4205490F7Q40871820-7CF7FA4E-0B62-4231-8DCA-59F0C907975BQ42369564-AB2BE6AB-4487-41CA-9CA3-F0A7E52BB31EQ43601788-AABCA2C9-B7EB-4E85-8B4D-06CD575FC2E3Q47159555-9C934043-6388-46A7-A60D-A68FDDEEEA0DQ47599682-020DC662-8244-4DD4-B9CC-0E0058A618B2Q47646742-C1BFFA53-3B75-4C58-8872-EDB402C641C8Q48857636-EF9CDE9E-E841-4684-B296-F8EA723193DB
P2860
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Phase I/II study of pegylated ...... tients with advanced melanoma.
@ast
Phase I/II study of pegylated ...... tients with advanced melanoma.
@en
Phase I/II study of pegylated arginine deiminase
@nl
type
label
Phase I/II study of pegylated ...... tients with advanced melanoma.
@ast
Phase I/II study of pegylated ...... tients with advanced melanoma.
@en
Phase I/II study of pegylated arginine deiminase
@nl
prefLabel
Phase I/II study of pegylated ...... tients with advanced melanoma.
@ast
Phase I/II study of pegylated ...... tients with advanced melanoma.
@en
Phase I/II study of pegylated arginine deiminase
@nl
P2093
P2860
P1476
Phase I/II study of pegylated ...... tients with advanced melanoma.
@en
P2093
Achim A Jungbluth
Anna C Pavlick
Bor-Wen Wu
Eric W Hoffman
Jedd D Wolchok
John S Bomalaski
Lloyd J Old
Neeta Pandit-Taskar
Patrick A Ott
P2860
P2888
P304
P356
10.1007/S10637-012-9862-2
P577
2012-08-05T00:00:00Z
P6179
1034251924